Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Genedrive to present data for its Hepatitis-C test at International Liver Conference

Data will be presented to a host of industry professionals at the event in Amsterdam
Genedrive's HCV ID Kit
The conference is taking place between 19-23 April

Genedrive PLC (LON:GDR) is to showcase data for its rapid diagnostic device for Hepatitis-C (HCV) to industry professionals at the International Liver Conference in Amsterdam later this month.

The clinical validation data for the Genedrive HCV ID Kit will be presented at the conference by Dr Darragh Duffy from the Institut Pasteur in Paris, one of the world’s leading research centres.

Genedrive’s HCV assay provides on-the-spot results in just 90 minutes direct from a very small plasma sample.

The trials revealed the technology was highly accurate and performed well against the best-in-class device.

Get the best of Proactive delivered straight to your inbox by singing up for our newsletter

“The Genedrive HCV assay will allow decentralised laboratories to provide affordable onsite molecular testing for HCV that aligns with recent WHO testing guidelines," said chief executive David Budd.

“With the wider availability of generic direct acting antiviral agents, the drive in resource limited countries is to cost effectively identify and treat individuals with Hepatitis C.

“We believe that with the performance achieved by the Genedrive HCV assay, there is an opportunity to play a very meaningful role in this strategy.”

CE certification in the works

The molecular diagnostics firm recently submitted the HCV ID Kit for certification under the EU Medical Devices Directive, the receipt of which would green-light the commercialisation of the product in the EU.

Shares opened almost 3% higher at 43.7p on Tuesday.

View full GDR profile View Profile

Genedrive PLC Timeline

Related Articles

biotechLatest.jpg
March 28 2017
2017 is going to be quite action packed we believe we have positioned the company for when RNA interference transforms from a technology to its promise of a new class of therapeutics - boss Ali Mortazavi.
shutterstock_216375733.jpg
January 24 2017
At the moment, the healthcare firm M Pharma is a work in progress
The Hydroponics Company: Access latest PPT from Proactive's CEO Sessions
May 19 2017
Dr Andrew Beehag talked medical cannabis products and pathways with investors.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use